The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Natural antioxidants in Alzheimer's disease
Open accessAbstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by severe cognitive impairment that ultimately leads to death. Current drugs used in AD are acetylcholinesterase inhibitors and antagonists to the NMDA receptors. These drugs may only slightly improve cognitive functions but have only very limited impact on the clinical course of the disease. In the past several years, based on in vitro and in vivo studies in laboratory animals, natural antioxidants, such as resveratrol, curcumin and acetyl-L-carnitine have been proposed as alternative therapeutic agents for AD. An increasing number of studies demonstrated the efficacy of primary antioxidants, such as polyphenols, or secondary antioxidants, such as acetylcarnitine, to reduce or to block neuronal death occurring in the pathophysiology of this disorder. These studies revealed that other mechanisms than the antioxidant activities could be involved in the neuroprotective effect of these compounds. This paper discusses the evidence for the role of acetylcarnitine in modulating redox-dependent mechanisms leading to the upregulation of vitagenes. Furthermore, future development of novel antioxidant drugs targeted to the mitochondria should result in effectively slowing disease progression. The association with new drug delivery systems may be desirable and useful for the therapeutic use of antioxidants in human neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 3×
“The vitagene family is composed of the Hsps haem oxygenase-1 (HO-1), Hsp70 and by the thioredoxin (Trx) system [53-55] .”
BackgroundSelf-citationMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Lauderback, C. M., Hackett, J. M., Huang, F. F., Keller, J. N., Szweda, L. I., Markesbery, W. R., & Butterfield, D. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00451.x · Cited by 464 · cited 1×
“The brain of an AD patient has been reported to be under oxidative stress, and this may play an important role in the pathogenesis and progression of AD [16-18] .”
BackgroundSelf-citationChen, C.-Y., Jang, J.-H., Li, M.-H., & Surh, Y.-J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.237 · Cited by 428 · cited 1×
“Recently, resveratrol has been demonstrated to increase the expression of HO-1 in PC12 cells and primary neuronal cultures, presumably through the activation of NF-E2-related factor 2 (Nrf2) in PC12 cells [60,61] .”
BackgroundInhibition of cancer growth by resveratrol is related to its low bioavailability
Asensi, M., Medina, I., Ortega, A., Carretero, J., Baño, M. C., Obrador, E., & Estrela, J. M. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00911-5 · Cited by 388 · cited 1×
“It is noteworthy to mention that in rodents and rabbits the tissue concentrations of resveratrol are always below 1 nmol/g fresh tissue [36,44] , whereas in humans the organs in which resveratrol shows greater accumulation are intestinal mucosa, stomach, liver and kidney, but the exact concentrations have not been est…”
BackgroundButterfield, D. A., Poon, H. F., St. Clair, D., Keller, J. N., Pierce, W. M., Klein, J. B., & Markesbery, W. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.002 · Cited by 377
Self-citationCarnitine status of lactoovovegetarians and strict vegetarian adults and children
Lombard, K. A., Olson, A. L., Nelson, S. E., & Rebouche, C. J. (1989) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/50.2.301 · Cited by 142
Lüth, H. J., Holzer, M., Gertz, H.-J., & Arendt, T. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02178-2 · Cited by 105 · cited 1×
“There is also strong evidence to suggest that both p21ras and p21ras-dependent MAP-kinase pathways are strongly induced in AD, and an aberrant expression of p21 is highly colocalised with an aberrant expression of NOS in this condition [34,35] .”
Background
Cited by
Flanagan, J. L., Simmons, P. A., Vehige, J., Willcox, M. D., & Garrett, Q. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-30 · Cited by 611
“have suggested that there may be mechanisms beyond antioxidant activities playing a neuroprotective role [118].”
BackgroundSuperoxide Dismutase Mimics: Chemistry, Pharmacology, and Therapeutic Potential
Batinić-Haberle, I., Rebouças, J. S., & Spasojević, I. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2876 · Cited by 531
Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies
Chew, H., Solomon, V. A., & Fonteh, A. N. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00598 · Cited by 353
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases
Sun, A. Y., Wang, Q., Simonyi, A., & Sun, G. Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-010-8111-y · Cited by 329
Metadata
- Authors
- Mancuso, C., Bates, T. E., Butterfield, D. A., Calafato, S., Cornelius, C., Lorenzo, A. D., Dinkova Kostova, A. T., & Calabrese, V.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2007-11-28
- Volume
- 16
- Issue
- 12
- Pages
- 1921-1931
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2096322266
- Cited by
- 159
- References
- 11
- FWCI
- 7.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.